About us

Who are we, and why are we passionate about pigs? At Sus Clinicals, our mission is to help accelerate the development of breakthrough therapeutics. We believe faster, more efficient pre-clinical testing is the key to getting life-saving treatments to patients sooner. Using a “pig as a platform” approach, we can generate tumors and other diseases on demand in our Oncopig®, then perform customized testing with our client’s medical device, drug, or diagnostic to give them the predictive data they need to move these therapies to the clinic faster.

Our story

Oncopig Cancer Model®


  • Successful induction of glioma


  • Expansion of models with successful inductions in lung, colon, bladder


  • Successful inductions in kidney


  • Patent application filed for targeted patch-based tumor induction technology


  • Sus Clinicals licenses first inducible large animal cancer model (Oncopig®) from University of Illinois
  • Patent application filed for “Modeling Oncology on Demand”
  • Model validated via liver tumor inductions

Regulatory Recognition


  • FDA clears streamlined process for shipping Oncopigs to research sites


  • FDA Center for Veterinary Medicine recognizes Oncopig production sites


  • Sus Clinicals receives FDA clearance for transgenic Oncopig

Biomedical Models


  • Sus Clinicals licenses breakthrough cell line technology to advance large animal preclinical research capabilities
  • Sus Clinicals licenses new Oncopig hybrid with increased capability for comorbidities
  • National Cancer Institute awards Sus Clinicals $2 million SBIR Phase II grant for drug targeting and liquid biopsy


  • First demonstration of comorbidity via imaging

Meet our leadership team

Jeffrey D. Weedman

Chief Executive Officer & Co-Founder

Dr. Larry Schook

Chief Scientific Officer & Co-Founder

Stephen J. Baggott

Chief Operating Officer

Geoffrey T. Marshall

Chief Financial Officer

Dr. Kyle M. Schachtschneider

VP of R&D and Services

Get in touch

"*" indicates required fields

Our mission

Enable our healthcare client partners to accelerate breakthrough therapeutics via transformative predictive preclinical research, helping to save lives.

"At Sus Clinicals we have the expertise to help our healthcare partners qualify innovative treatments where cancer becomes a bump in the road, not the end of the road."
Jeff Weedman
CEO & Co-Founder


Sus Clinicals scientific headquarters is in Chicago, IL. We have two full labs in Chicago, supporting work for clients and internal R&D. We also have lab facilities in Urbana, IL. Our commercial operations are located in Cincinnati, OH.

Ethics and governance

Sus Clinicals always strives to adhere to the highest standards of ethical behavior in all we do. We and our research partners comply with all applicable laws and regulations, including standards for the use of biomedical research animals. These include best practices as set forth by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and the American Association for Laboratory Animal Science (AALAS). We conduct our research with robust team training, comprehensive quality assurance and integrated data management practices. We are also committed to transparency, including disclosing any conflicts of interest that may arise in the course of our work. As part of this, we ensure compliance with requirements under any government-funded or other sponsored research, which includes having a clearly defined Financial Conflict of Interest in Research (FCOIR) policy (Click here to view PDF)